LigoCyte Initiates Third Human Clinical Trial For Norovirus Vaccine

LigoCyte Pharmaceuticals (LigoCyte) has initiated its third human clinical trial of its norovirus vaccine. The phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered, dry powder vaccine in healthy adults.

LigoCyte’s norovirus vaccine is a needle-free, dry powder formulation based on virus like particle (VLP) antigens, which are highly purified protein products.

Reportedly, the study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo. Clinical studies to date have shown the vaccine to be immunogenic and generally well tolerated in human subjects.